Inhibition of intestinal tumorigenesis via selective inhibition of COX-2

  • R. N. Dubois
  • H. Sheng
  • J. Shao
  • C. Williams
  • R. D. Beauchamp


Clinical studies have shown a 40–50% reduction in relative risk of colorectal cancer in individuals taking aspirin on a regular basis 1–6. Persons with familial adenomatous polyposis (FAP) who take sulindac show a striking reduction in adenoma size and number7–11. Since a potential target of these drugs is the cyclooxygenase (COX) enzymes, we set out to determine if COX-1 or -2 was dysregulated during the malignant transformation of intestinal epithelial cells.


Familial Adenomatous Polyposis Colorectal Tumorigenesis Transform Growth Factor Beta Receptor Intestinal Tumorigenesis Sulindac Sulfide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N Eng J Med. 1995; 333: 609–614.CrossRefGoogle Scholar
  2. 2.
    Greenberg ER, Baron JA, Freeman DHJ, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst. 1993; 85: 912–916.PubMedCrossRefGoogle Scholar
  3. 3.
    Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991; 325: 1593–1596.PubMedCrossRefGoogle Scholar
  4. 4.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CWJ. Aspirin use and risk of fatal cancer. Cancer Res. 1993; 53: 1322–1327.PubMedGoogle Scholar
  5. 5.
    Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 1994; 154: 394–399.PubMedCrossRefGoogle Scholar
  6. 6.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994; 121:241–246.PubMedGoogle Scholar
  7. 7.
    Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328: 1313–1316.PubMedCrossRefGoogle Scholar
  8. 8.
    Waddell WR, Loughry RW Sulindac for polyposis of the colon. J Surg Oncol. 1983 24: 83–87.PubMedCrossRefGoogle Scholar
  9. 9.
    Waddell WR, Gasner GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg. 1989; 157: 175–178.PubMedCrossRefGoogle Scholar
  10. 10.
    Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis. 1993; 8: 13–17.PubMedCrossRefGoogle Scholar
  11. 11.
    Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993; 80: 1618–1619.PubMedCrossRefGoogle Scholar
  12. 12.
    Eberhart CE, Coffey RJ, Radhika A et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107: 1183–1188.PubMedGoogle Scholar
  13. 13.
    Kargman S, O’Neill G, Vickers P, Evans J, Mancini J, Jothy S. Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res. 1995; 55: 2556–2559.PubMedGoogle Scholar
  14. 14.
    Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res. 1995; 55: 3785–3789.PubMedGoogle Scholar
  15. 15.
    DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology. 1996; 110: 1259–1262.PubMedCrossRefGoogle Scholar
  16. 16.
    Williams CW, Luongo C, Radhika A et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 1996; 111: 1134–1140.PubMedCrossRefGoogle Scholar
  17. 17.
    Reddy BS, Rao CV, Siebert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996; 56: 4566–4569.PubMedGoogle Scholar
  18. 18.
    Prescott SM, White RL. Self promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 1986; 87: 783–786.CrossRefGoogle Scholar
  19. 19.
    Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell. 1996; 87: 803–809.PubMedCrossRefGoogle Scholar
  20. 20.
    Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA. 1994; 91: 3228–3232.PubMedCrossRefGoogle Scholar
  21. 21.
    DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Invest. 1994; 93: 493–498.PubMedCrossRefGoogle Scholar
  22. 22.
    Coffey RJ, Hawkey CJ, Damstrup L et al. EGF receptor activation induces nuclear targeting of COX-2, basolateral release of prostaglandins and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA. 1997; 94: 657–662.PubMedCrossRefGoogle Scholar
  23. 23.
    DuBois RN, Shao J, Sheng H, Tsujii M, Beauchamp RD. G1 delay in intestinal epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 1996; 56: 733–737.PubMedGoogle Scholar
  24. 24.
    Wang J, Sun L, Myeroff L et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumour suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem. 1995; 270: 22044–22049.PubMedCrossRefGoogle Scholar
  25. 25.
    Kutchera W, Jones DA, Matsunami N et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA. 1996; 93: 4816–4820.PubMedCrossRefGoogle Scholar
  26. 26.
    Beazer-Barclay Y, Levy DB, Moser AR et al. Sulindac suppresses tumorigenesis in the min mouse. Carcinogenesis. 1996; 17: 1757–1760.PubMedCrossRefGoogle Scholar
  27. 27.
    Jacoby RF, Marshall DJ, Newton MA et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the non-steroidal anti-inflammatory drug Piroxicam. Cancer Res. 1996; 56: 710–714.PubMedGoogle Scholar
  28. 28.
    Boolbol SK, Dannenberg AJ, Chadburn A et al. Cyclooxygenase-2 overexpression and tumour formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996; 56: 2556–2560.PubMedGoogle Scholar
  29. 29.
    Piazza GA, Rahm AL, Krutzsch M et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995; 55: 3110–3116.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • R. N. Dubois
  • H. Sheng
  • J. Shao
  • C. Williams
  • R. D. Beauchamp

There are no affiliations available

Personalised recommendations